Pfizer Deal Will Help Propel Aurobindo's Revenues To $2 Billion In Three Years
This article was originally published in The Pink Sheet Daily
Executive Summary
Aurobindo's deal with Pfizer encompasses nearly 100 products, mostly tablets and capsules and a few injectables, to be sold in 70 geographies, including the U.S. and Europe..
You may also be interested in...
Pfizer Ahead Of Guidance In India, President Of Established Products Business Unit David Simmons Tells PharmAsia News
David Simmons, President at Pfizer's Established Products Business Unit says he is very positive about his company's deals struck earlier this year with Aurobindo and Claris. The two Indian companies will help Pfizer bulk up more than 100 oral and injectable formulations and turn the business unit cash positive in the next two to three years. Pfizer will sell the loss-of-exclusivity products through its Greenstone arm in the United States will likely launch those in Europe, Japan and a host of emerging markets. PharmAsia News' India bureau sat down with Simmons to find out more about Pfizer's pipeline and plans in India.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.